Oppenheimer reissued their buy rating on shares of Urogen Pharma (NASDAQ:URGN) in a report issued on Tuesday morning.
A number of other equities research analysts also recently weighed in on URGN. HC Wainwright initiated coverage on Urogen Pharma in a report on Tuesday, January 29th. They issued a buy rating and a $82.00 price target for the company. Raymond James set a $57.00 price objective on Urogen Pharma and gave the company a buy rating in a research report on Friday, March 1st. Finally, Stifel Nicolaus restated a buy rating and set a $63.00 price objective on shares of Urogen Pharma in a research report on Tuesday, March 5th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus target price of $68.40.
Shares of NASDAQ URGN opened at $38.02 on Tuesday. Urogen Pharma has a twelve month low of $34.61 and a twelve month high of $69.57. The company has a market capitalization of $524.01 million, a PE ratio of -7.92 and a beta of 1.48.
Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings results on Thursday, February 28th. The company reported ($1.46) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.24) by ($0.22). Urogen Pharma had a negative net margin of 4,296.08% and a negative return on equity of 70.67%. On average, sell-side analysts predict that Urogen Pharma will post -5.47 earnings per share for the current fiscal year.
In related news, insider Mark Schoenberg sold 1,991 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $37.30, for a total transaction of $74,264.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Hedge funds have recently made changes to their positions in the business. Parallel Advisors LLC boosted its position in Urogen Pharma by 100.0% during the 4th quarter. Parallel Advisors LLC now owns 1,000 shares of the company’s stock worth $43,000 after acquiring an additional 500 shares during the period. Russell Investments Group Ltd. acquired a new position in Urogen Pharma during the 3rd quarter worth $119,000. Van ECK Associates Corp boosted its position in Urogen Pharma by 27.6% during the 4th quarter. Van ECK Associates Corp now owns 4,364 shares of the company’s stock worth $188,000 after acquiring an additional 944 shares during the period. WINTON GROUP Ltd acquired a new position in Urogen Pharma during the 3rd quarter worth $221,000. Finally, JPMorgan Chase & Co. acquired a new position in Urogen Pharma during the 3rd quarter worth $320,000. Institutional investors own 69.71% of the company’s stock.
About Urogen Pharma
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.
Read More: How is inflation measured?
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.